Nonsynonymous Polymorphisms in the Human AS3MT Arsenic Methylation Gene: Implications for Arsenic Toxicity

Jiaojiao Li, Charles Packianathan, Toby G. Rossman, and Barry P. Rosen

ABSTRACT: Arsenic methylation, the primary biotransformation in the human body, is catalyzed by the enzyme As(III) S-adenosylmethionine (SAM) methyltransferases (hAS3MT). This process is thought to be protective from acute high-level arsenic exposure. However, with long-term low-level exposure, hAS3MT produces intracellular methylarsenite (MAs(III)) and dimethylarsenite (DMAs(III)), which are considerably more toxic than inorganic As(III) and may contribute to arsenic-related diseases. Several single nucleotide polymorphisms (SNPs) in putative regulatory elements of the hAS3MT gene have been shown to be protective. In contrast, three previously identified exonic SNPs (R173W, M287T, and T306I) may be deleterious. The goal of this study was to examine the effect of single amino acid substitutions in hAS3MT on the activity of the enzyme that might explain their contributions to adverse health effects of environmental arsenic. We identified five additional intragenic variants in hAS3MT (H51R, C61W, I136T, W203C, and R251H). We purified the eight polymorphic hAS3MT proteins and characterized their enzymatic properties. Each enzyme had low methylation activity through decreased affinity for substrate, lower overall rates of catalysis, or lower stability. We propose that amino acid substitutions in hAS3MT with decreased catalytic activity lead to detrimental responses to environmental arsenic and may increase the risk of arsenic-related diseases.

INTRODUCTION

Arsenic is a toxic metalloid that is the 20th most abundant element in the Earth’s crust.1 Arsenic in bedrock is released into groundwater that is used to grow food and as drinking water, causing a worldwide health hazard that affects tens of millions of people.2 Inorganic arsenic (iAs) is transformed primarily to methylated arsenicals MAs(III) and DMAs(III) and, to a lesser extent, to trimethylarsine (TMAs(III)) by the enzyme As(III) S-adenosylmethionine (SAM) methyltransferase (AS3MT in mammals and ArsM in microbes).3,4 Methylated arsenicals are excreted in urine, where they are abiotically oxidized in air to arsenicals inorganic arsenic (As(V), MAs(V), and DMAs(V)).10,11 In this study, the sums of trivalent products have been shown to be more toxic6−8 and potentially more carcinogenic9 than inorganic arsenic. MAs(III) and DMAs(III) are eventually excreted in urine, where they are abiotically oxidized in air to iAs(III) S-adenosylhomocysteine (SAH) by the enzyme As(III) S-adenosylmethionine (SAM) methyltransferase (AS3MT in mammals and ArsM in microbes).3,4

Human AS3MT (hAS3MT) produces MAs(III) and DMAs(III) primarily in liver.5 These trivalent products have been shown to be more toxic6−8 and potentially more carcinogenic9 than inorganic arsenic. MAs(III) and DMAs(III) are eventually excreted in urine, where they are abiotically oxidized in air to MAs(V) and DMAs(V).10,11 In this study, the sums of trivalent and pentavalent inorganic and methylated urinary arsenic are termed iAs, MAs, and DMAs, respectively. High urinary levels of MAs relative to DMAs are a susceptibility factor correlated with arsenic-related diseases.5,12−14 In contrast, a higher ratio of DMAs/MAs in urine is considered protective, perhaps because it reflects more rapid clearance of arsenic from the body.15 Other factors that might influence urinary levels are redox pathways such as glutathione synthesis and reduction,16 channels, permeases and pumps such as aquaglyceroporins, glucose permeases, phosphate permeases, and ABC ATPases that transport arsenicals in and out of tissues.17

The most frequent distribution of arsenic metabolites in human urine is 10−30% inorganic As, 10−20% MAs, and 60−70% DMAs, but there are large individual variations.5,15 Some variations are associated with single nucleotide polymorphisms in the hAS3MT gene.15 Most SNPs are neutral and have little effect on health or development.19 However, a M287T SNP in hAS3MT has been associated with higher risk of arsenic-related disease such as diabetes,20 skin lesions,21,22 and cancer.13,15,23 Polymorphisms in the hAS3MT gene have been associated with altered arsenic metabolite patterns among different populations including those in Bangladesh, Argentina, Mexico, Taiwan, and Central Europe.24−28 For example, one protective hAS3MT haplotype that produces low urinary excretion of MAs (~7.5%) and a higher percentage of DMAs (~78%) is found in indigenous populations in the Argentinean Andes exposed for generations to elevated arsenic in their water supply (0.8 mg/L).15,28,29 The increased ratio of DMAs/MAs in urine in this population may reflect natural selection for SNPs in the noncoding region of the hAS3MT gene that increases expression of the gene, leading to increased arsenic tolerance. Inhabitants of Camarones in the Arica y Parinacota Region in...
Chile exposed to >1 mg/L of arsenic in their drinking water have four protective genetic variants of the hAS3MT gene (G12390C, C14215T, T14458C, and G35991A). These variants are associated with more efficient arsenic metabolism and suggest human adaptation to persistent high levels of arsenic.

Until this study, only three SNPs that encode single amino acid changes in the hAS3MT protein, R173W, M287T, and T306I, have been identified. These three exonic SNPs are found in the AS3MT coding region of African-Americans and Caucasian-Americans. They reported that the M287T SNP has a frequency of about 10% in both populations, the R173W SNP has a minor allele frequency of 0.8% in the African-American population, and the T306I SNP has a minor allele frequency of 0.8% in just one sample of Caucasian-Americans. The most common polymorphism, M287T, has been associated with lower overall methylation capacity, with lower primary (MAS/iAs) and secondary (DMAs/MA) urinary methylation ratios (PMI and SMI, respectively) in different populations.

In this study, we prepared human genomic data and identified five new non-synonymous missense variants. Including the three previously known, these eight were further analyzed. The location of these single amino acid substitutions in the sequence of hAS3MT is shown in Supplemental Figure S1. The goal of the project was to determine the consequences of the single amino acid substitutions on the ability of these enzymes to methylate arsenic and whether structural information can be used to predict the effect of the substitutions. Knowledge of the enzymatic mechanism of AS3MT is crucial for understanding its paradoxical role in protection from arsenic exposure and its transformation of arsenic into more toxic methylated species, information that can only be acquired from studies with purified enzyme. We previously synthesized a gene for hAS3MT optimized for bacterial expression, which allowed purification of highly active AS3MT. We introduced each mutation into the synthetic hAS3MT gene and purified the resulting enzymes. We compared their enzymatic properties and stability with the most common form of hAS3MT (termed wild type in this study) using either As(III) or MAs(III) as substrate. The location of each substitution in the structure of hAS3MT was identified using a homology structural model of hAS3MT, allowing correlation of structure with enzymatic properties. From our results, individuals with any of the eight variants would be predicted to have a longer total arsenic retention time in the body, leading to elimination of more iAs and MAs and less DMAs with a lower urinary DMAs/MAs ratio. These individuals could be at greater risk for arsenic-related diseases.

### MATERIALS AND METHODS

**Reagents.** SAM was purchased from Cayman Chemical Co., Ann Arbor, MI. A stock solution of tris(2-carboxyethyl)phosphine (TCEP) was prepared at 0.5 M and adjusted to pH 7.0. MAs(V) was reduced to MAs(III) using either As(III) or MAs(III) as the substrates of for methylation were the glutathione (GSH) conjugates As(GS)3 and MAs(GS)2, which were prepared by incubation of 1 mM As(III) or MAs(III) with a four-fold molar excess of GSH for 5 h at 23 °C in degassed buffers under argon, as described. All other reagents were purchased from commercial sources and were of analytical grade or better.

**Strains, Media, and Growth Conditions.** Escherichia coli Stellar (Clontech Laboratories, Mountain View, CA) was used for plasmid DNA construction and replication. For most experiments, cultures of E. coli bearing the indicated plasmids were grown aerobically in Luria–Bertani (LB) at 37 °C with 100 μg/mL ampicillin or 50 μg/mL kanamycin, as required, with shaking. Bacterial growth was monitored by measuring the optical density at 600 nm (OD600 nm).

**Construction of hAS3MT Variants.** The synthetic hAS3MT gene was cloned into expression vector pMAL-c2x that produces a fusion with the maltose binding protein gene at the 3′ end and eight histidine residues at the 3′ end. The eight mutations in the synthetic hAS3MT gene were introduced by site-directed mutagenesis using a QuickChange mutagenesis kit (Stratagene, La Jolla, CA). The oligonucleotides used for mutagenesis are listed in Supplemental Table S1. Each hAS3MT mutation was confirmed by commercial DNA sequencing (Sequetech, Mountain View, CA).

**Protein Expression and Purification.** Wild-type AS3MT (87 837 Da) and variant enzymes with were purified by Ni-NTA chromatography, as described. Protein concentrations were estimated from A280 nm using ε = 93 080 M−1 cm−1. hAS3MT-containing fractions were rapidly frozen and stored at −80 °C until use. Thioredoxin (Trx) and thioredoxin reductase (TR) were prepared as described. All buffers were degassed by bubbling with argon for 30 min before use.

**Assays of Arsenic Methylation.** hAS3MT activity was assayed with two different procedures. The time-resolved Förster resonance energy transfer (TR-FRET) assay measures conversion of SAM to S-adenosylhomocysteine (SAH) at short times using an EPIgeneous methyltransferase assay kit (Cambio Bioassays, Bedford, MA). The assay was carried out using a low volume 384-well microtiter plate in a buffer consisting of 50 mM NaH2PO4, pH 8.0, containing 0.3 M NaCl, 1 μM purified hAS3MT, 0.5 mM GSH, 1 μM Trx, 0.3 mM TR, and 0.03 mM NADPH and 10 μM of either As(GS)3 or MAs(GS)3, unless otherwise indicated. The plates were incubated at 37 °C for 2 min with shaking in an Eppendorf ThermoMixer C before addition of SAM at 10 μM, final concentration (unless otherwise indicated), to initiate the reaction. The reactions incubated for 1, 2, and 5 min and were terminated and developed by addition of the SAH-d2 and anti-SAH Lumi4-Tb detection reagents. The plates were incubated for 1 h, and fluorescence was measured at both 665 and 620 nm with excitation at 337 nm in a Synergy H4 Hybrid Multi-Mode microplate reader. The homogeneous time-resolved fluorescence (HTRF) was calculated from the ratio of emission at 665 and 620 nm. The concentration of SAH was calculated with a calibration curve constructed with known concentrations of SAH. The reaction was linear over 5 min, and initial rates were calculated from the slope.

For measurement at longer times and for speciation of the products, high pressure liquid chromatography (HPLC) was used, with arsenic concentrations determined by inductively coupled plasma mass spectrometry (ICP-MS). The assay mixture contained 1 μM purified hAS3MT, 2.5 mM GSH, 10 μM Trx, 1.5 mM TR, 0.3 mM NADPH and 10 μM of either As(GS)3 or MAs(GS)3, unless otherwise indicated) in a buffer consisting of 50 mM NaH2PO4, and 0.3 M NaCl, pH 8. SAM was added at a final concentration 0.5 mM to initiate the reaction at 37 °C. For initial rate determinations of SAM kinetics, the reactions were carried out for 5, 10, and 20 min at the indicated SAM concentrations. The reaction was linear over this time period, and the slope was used to estimate the initial rate. To recover all of the arsenic, the reactions were terminated by addition of H2O2 at 10% (v/v), final concentration, which also oxidizes all arsenicals, so the products will be termed MAs and DMAs. The assay solution was immediately passed through a 3 kDa cutoff Amicon ultrafilter (Millipore, Billerica, MA), and speciation of arsenic in the filtrate was determined by HPLC (PerkinElmer Series 2000) with a C18 300A reverse-phase column (Chromsolv s.r.o., Brno, Czech Republic), with the arsenic concentration measured by ICP-MS using an ELAN 9000 (PerkinElmer, Waltham, MA). As(III), MAs(III), DMAs(V), MAs(V), and As(V) were used at 1 μM as standards.

**MATERIALS AND METHODS**

**Reagents.** SAM was purchased from Cayman Chemical Co., Ann Arbor, MI. A stock solution of tris(2-carboxyethyl)phosphine (TCEP) was prepared at 0.5 M and adjusted to pH 7.0. MAs(V) was reduced to trivalent MAs(III) using Na2S2O4, Na2S2O5 and H2SO4 and adjusted to pH 6.5 with NaOH, as described. The identities of the reduction products were confirmed by high performance liquid chromatography (HPLC) coupled to inductively coupled plasma mass spectroscopy (ICP-MS), as described. The substrates for methylation were the glutathione (GSH) conjugates As(GS)3 and MAs(GS)3, which were prepared by incubation of 1 mM As(III) or MAs(III) with a four-fold molar excess of GSH for 5 h at 23 °C in degassed buffers under argon, as described. All other reagents were purchased from commercial sources and were of analytical grade or better.
Methylation in cells of *E. coli* BL21(DE3) expressing hAS3MT wild type and mutants was assayed by growing cells in 2 mL of LB medium in the presence of 0.3 mM IPTG, 10 μg/mL kanamycin, and 10 μM of either As(III) or 2 μM MAs(III) at 37 °C for 12 h. The cell were harvested, washed, and suspended in ST-1 medium with 2 μM MAs(III) and then grown for 3 h at 37 °C. Arsenicals were speicated by HPLC using a C18 reverse phase column, and the amount of arsenic was estimated by ICP-MS.

**Assays of Thermal Stability.** Thermal stability was assayed by incubation of the enzyme at 42 °C for the indicated times in a buffer consisting of 50 mM NaH2PO4 and 0.3 M NaCl, pH 8. The reaction was terminated rapid cooling on ice, and methylation activity determined with the TR-FRET assay for 5 min at 37 °C. t1/2 values were calculated using SigmaPlot (Systat Software, Inc., San Jose, CA).

**Sources of Single Nucleotide Polymorphisms.** hAS3MT SNPs were identified from the Ensembl genome browser, which contains 1000 genomes, NHLBI GO Exome Sequencing Project (ESP), Exome Aggregation Consortium (ExAC), NHLBI Exome Sequencing Project, CLINSEQ SNP: CSAGilent and the HapMap Project repositories of human genome data.

**Homology Model of the hAS3MT Structure with Polymorphic Residues.** A homology model of hAS3MT was built on the structure of PhAs(III)-bound CmArsM (PDB ID: 4K7W) from residues 44–371 (residue numbers based on the CmArsM sequence) using a fully automated protein structure homology modeling server SWISS-MODEL (http://swissmodel.expasy.org/) (Figure 1A). The model quality was estimated based on the QMEAN scoring function. The final homology model incorporated 308 of those 328 residues. To place SAM in the model, in silico docking with SAM was carried out using the PATCHDOCK server. The docked hAS3MT model with SAM was superimposed with the As(III)-bound structure of CmArsM (PDB ID: 4FSF) to acquire the arsenic atom in the As(III) binding site of hAS3MT. PyMOL v1.3 was used to visualize the structural models. The model for each of the polymorphic variants was built similarly and superposed with each other to locate the position of the polymorphic residues (Figure 1B).

**RESULTS**

**Missense Polymorphisms in hAS3MT and Population Frequencies.** Because of the importance of arsenic metabolic reaction in humans, one objective was to determine whether the human hAS3MT gene, like many other human methyltransferase genes, includes additional functional genetic polymorphisms. From database searches, we identified 891 sequence variants in the AS3MT gene. Eight nonsynonymous missense variants that result in single amino acid changes in the AS3MT protein were chosen for further analysis using the following criteria: (1) previously known (R173W, M287T, and T306I), (2) location in the As(III) (C61W and W203C) SAM binding (H51R and I136T) domains, and (3) high PolyPhen2 scores (R251H, R173W, and W203C). The PolyPhen2 algorithm predicts the possible impact of an amino acid substitution on the structure and function of a human protein. On the basis of the Exome Aggregation Consortium (ExAC) database, which has a large sample size, the order of the minor allele frequency (MAF) of these missense SNPs is as follows: WT > M287T (9.4%) > C61W (∼0.5%) > R173W (∼0.11%) > R251H (∼0.1%) > T306I (∼0.02%) > W203C (∼0.004%) > H51R (∼0.002%) (Table 1). Information on the frequency of I136T is not available. Additional details of each polymorphism in individual populations are given in Supplemental Tables S2–S9. The M287T SNP has highest allele frequency (8–11%) and genotype (13–24%) frequency in the global population. A homozygous recessive genotype has been found only for the M287T polymorphism in several populations, with a frequency of about 1% (Supplemental Table S8). Genotype frequencies of C61W, I136T, W203C, and T306I are unknown. Other missense SNPs (H51R, R173W, and R251H) were identified only in heterozygous individuals. For the 1000 Genomes Project, all donors were over 18 and declared themselves to be healthy at the time of collection (http://www.internationalgenome.org/faq/can-i-get-phenotype-gender-and-family-relationship-information-samples/).

**Homology Model of hAS3MT and Polymorphisms.** We modeled the structure of hAS3MT and its variants on the structure of the CmArsM As(III) SAM methyltransferases from the eukaryotic alga *Cyanidioschyzon merolae* sp. SS08. We mapped the location of the eight residues that are represented with the intragenic polymorphisms on this hAS3MT homology
A single amino acid polymorphic enzymes were compared with wild-type hAS3MT at 30 min using either As(III) (Figure 2B) or MAs(III) (Figure 2C) as substrate. With As(III) as substrate, the reaction measures a combination of both the first (As → MAs) and second methylation (MAs → DMAs) steps when assayed with HPLC−ICP−MS. MAs(III) is both the product of the first methylation step and is the substrate of the second methylation step, so with MAs(III) as substrate, the reaction measures only the second round of methylation (MAs → DMAs). Using As(III) as substrate, the eight polymorphic enzymes showed lower methylation activity compared to wild-type hAS3MT in the following order: WT > M287T > R251H > T306I > R173W > H51R > I136T. The C61W and W203C derivatives exhibited essentially no catalytic activity and were comparable to the inactive C206S mutant.

Using MAs(III) as substrate to assay the second round of methylation, the order of methylation activity was similar to the results with As(III) as substrate with one exception. The C61W and W203C derivatives exhibited essentially no catalytic activity and were comparable to the inactive C206S mutant.

Table 1. Frequencies of the Eight Missense hAS3MT Polymorphisms in the 1000 Genomes Project, ExAC, NHLBI Exome Sequencing Project, or PUSHMAN Population*.

| dbSNP rs no. (MAF from ExAC) | residue change | allele change | allele frequency (numbers of individuals): top, ancestral; bottom, variants | genotype frequency (numbers of individuals): top, homozygous dominant; middle, heterozygous; bottom, homozygous recessive | population |
|-----------------------------|----------------|--------------|-------------------------------------------------|-------------------------------------------------|------------|
| rs201702937 (0.002%)        | H51R           | a152g        | A: 0.9998 (5007) G: 0.000199 (1)                 | AIA: 0.9996 (2503) AIG: 0.00039 (1) GIG: 0       | 1000 Genomes Project (African, American, East Asian, European, South Asian) |
| rs80317306 (0.50%)          | C61W           | t183g        | T: 0.995 (120200) G: 0.005 (646)                 | NA                                              | Exome Aggregation Consortium (ExAC) individuals (African/African American, Latino, East Asian, Finnish, Non-Finnish European, South Asian and others) |
| rs112056792 (NA)            | I136T          | t407c        | T: 0.500 (1) C: 0.500 (1)                        | NA                                              | BUSHMAN POP (Northern Kalahari of Africa) |
| rs35232887 (0.11%)          | R173W          | c517t        | C: 0.999 (5003) T: 0.001 (5)                     | CIC: 0.998 (2499) CTI: 0.002 (5) TTI: 0          | 1000 Genomes Project (African, American, East Asian, European, South Asian) |
| rs370022454 (0.004%)        | W203C          | g609t        | G: 0.999734 (3763) T: 0.000265675 (1)            | NA                                              | NHLBI Exome Sequencing Project (African-American) |
| rs139656545 (0.10%)         | R251H          | g752a        | G: 0.998 (4997) A: 0.002 (11)                    | GIG: 0.996 (2493) AIG: 0.004 (11) TAI: 0         | 1000 Genomes Project (African, American, East Asian, European South Asia) |
| rs111914339 (9.4%)          | M287T          | t860c        | T: 0.923 (4622) C: 0.077 (386)                   | TIT: 0.854 (2138) CTI: 0.138 (346) CIC: 0.008 (20) | 1000 Genomes Project (African, American, East Asian, European, South Asia) |
| rs34556438 (0.02%)          | T306I          | c917t        | C: 0.99951 (8164) T: 0.000489716 (4)             | NA                                              | NHLBI Exome Sequencing Project (European-American) |

*Original data were mined from the Ensembl genome browser database (http://useast.ensembl.org/index.html) accessed April 5, 2017. For the 1000 Genomes Project, all donors were over 18 and declared themselves to be healthy at the time of collection. The health conditions for other data source populations are unknown.

Polymorphisms Affect hAS3MT Methylation Activity.

The enzymatic activity of the polymorphic AS3MTs was determined. Each variant was expressed in E. coli cells in about the same amount as wild-type hAS3MT, as shown by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) (Supplemental Figure S2). Arsenic methylation in cells of E. coli provides an initial screen for the effects of the mutations. Methylation in cells expressing the eight variants was compared with wild-type hAS3MT as a positive control and an inactive C206S mutant as a negative control (Supplemental Figure S3). Cells expressing six of the eight SNPs (H51R, I136T, R173W, R251H, M287T, and T306I) methylated As(III) to varying degrees, but only M287T activity was comparable to the wild type. Cells expressing C61W and W203C derivatives were unable to methylate As(III) (Supplemental Figure 3AS). Like the C206S mutant, cells expressing W203C derivative were unable to methylate MAs(III), but the cells expressing the C61W derivative retained ability to methylate MAs(III) (Supplemental Figure 3BS).

Purified wild-type hAS3MT rapidly methylated As(III) to the methylated species and more slowly to the dimethylated species (Figure 2A), consistent with our previous observations. At 30 min of reaction time, MAs accounted for approximately 25% of total arsenic, and DMAs accounted for about 30%, with 45% remaining as iAs. The methylation activity of purified single amino acid polymorphic enzymes were compared with microbial ArsMs and animal AS3MTs have four conserved cysteines and lack the cysteine corresponding to Cys32 in hAS3MT. The natural three-cysteine enzyme of Aspergillus fumigatus methylates MAs(III) but not As(III), similar to the C61W hAS3MT polymorphic enzyme.44
Figure 2. Arsenic methylation by wild-type hAS3MT and polymorphic variants. (A) Time course of As(III) methylation by wild-type hAS3MT. (B) As(III) methylation by wild-type hAS3MT and polymorphic variants. (C) MAs(III) methylation by wild-type hAS3MT and polymorphic variants. Methylation was assayed in mixture of 1 μM purified hAS3MT, 0.5 mM SAM, 2.5 mM GSH, 10 μM Trx, 1.5 μM TR, 0.3 mM NADPH, and 10 μM As(III) (A and B) or MAs(III) (C) in phosphate buffer, pH 8, at 37 °C. Samples were withdrawn at the indicated times (A) or 30 min (B and C), and the reaction terminated by addition of 10% (v/v) H₂O₂, final concentration, and arsenic species analyzed by HPLC−ICP−MS. The data are the means ± SE (n = 3).
as the ratio between the product and substrate.\textsuperscript{15,18,45} The primary methylation index (PMI) is defined as the ratio of MAs/iAs, and the secondary methylation index (SMI) is the ratio of DMAs/MAs.\textsuperscript{18} The SMI in urine has frequently been used as an operational indicator of methylation capacity of individuals exposed to inorganic arsenic and in studies of interindividual variability in susceptibility to adverse health effects associated with chronic exposure.\textsuperscript{46} Here we compared the in vitro methylation indexes of the eight polymorphic enzymes with wild-type hAS3MT calculated from the data in Figure 2B. The results show differences in both the PMI and SMI between the wild-type and polymorphic enzymes. In every case, both the SMI and PMI were lower than the wild-type values (Figure 3A). The wild-type enzyme had the highest (Figure 3B). The data demonstrate that SNPs with low methylation efficiency have higher percentages of iAs and MAs and lower percentages of DMAs compared to wild-type hAS3MT. After 30 min of reaction, wild-type AS3MT total arsenic was 38% As, 19% MAs, and 43% DMAs. The M287T, R251H, and T306I enzymes showed 58–61% inorganic As, 18–20% MAs, and 20–23% DMAs. H51R, I136T, R173W, C61W, and W203C had the highest amount of starting material iAs (83–100%) and lowest DMAs (0–8%). These results demonstrate that the eight nonsynonymous missense variants of hAS3MT have lower arsenic methylation capacity compared with wild-type hAS3MT, from which we predict may lead to individual variations in arsenic methylation and slower clearance of arsenic from the body, factors that could increase the risk of arsenic-related diseases.

Kinetic Analysis of hAS3MT Polymorphic Enzymes. Kinetics governs fluxes of metabolites through intracellular pathways. Enzymes catalyze the individual steps of cellular reactions, and their rates dictate which pathways predominate. The rate of production of individual methylated species, and hence the PMI and SMI, depends on the kinetics of each step, which may vary in different polymorphic variants. How do the kinetic properties of the polymorphic enzymes compare with the wild type? The kinetic parameters for each substrate, As(III), MAs(III), and SAM, were individually determined for wild-type and variant hAS3MTs. With the TR-FRET assay, the first (As → MAs) (Figure 4A) and second (MAs → DMAs) (Figure 4B) methylation steps can be assayed independently.\textsuperscript{35} In both steps, wild-type hAS3MT exhibited the highest maximal rates (V\textsubscript{max}) compared with the polymorphic enzymes. The R251H and T306I variants showed higher V\textsubscript{max} values compared to the other polymorphic enzymes. The V\textsubscript{max} values of the I136T, R173W, M287T, and H51R variants were significantly lower than the others in both reaction steps.

The affinity (K\textsubscript{m}) of each enzyme for As(III) and MAs(III) was determined (Table 2). Wild-type and polymorphic hAS3MT enzymes each had K\textsubscript{m} values in the range of 1–2 μM, indicating that the amino acid substitutions did not affect binding of As(III) (except for C61S and W203C, which do not methylate As(III)). The apparent K\textsubscript{m} values for MAs(III) were lower than for As(III) for each enzyme, in the range of 0.4–0.8 μM, suggesting that MAs(III) is a better substrate than As(III). The exceptions were W203C, which does not methylate MAs(III), and C61S, which has a three-fold reduction in affinity for MAs(III).

The TR-FRET assay measures formation of SAH from SAM and thus cannot be used for determination of SAM kinetics,\textsuperscript{35} so the kinetics for SAM as substrate was determined by HPLC–ICP–MS. This measures only the efficiency (k\textsubscript{cat}/K\textsubscript{m}) of each catalytic site of hAS3MT, with one site being sufficient to measure the entire enzyme. The affinity of each polymorphic enzyme for SAM was similar to that of the wild type, in the range of 14–30 μM with one exception. The K\textsubscript{m} for I136T for SAM was 137 μM, eight-fold lower affinity than wild-type hAS3MT. From the homology model of hAS3MT, Ile136 is in the SAM binding domain, suggesting that a threonine substitution affects folding of the SAM binding domain.

To obtain a more complete picture of the methylation cycle, the percentages of iAs, MAs, and DMAs were calculated (Figure 3B). The data demonstrate that SNPs with low methylation efficiency have higher percentages of iAs and MAs and lower percentages of DMAs compared to wild-type hAS3MT. After 30 min of reaction, wild-type AS3MT total arsenic was 38% As, 19% MAs, and 43% DMAs. The M287T, R251H, and T306I enzymes showed 58–61% inorganic As, 18–20% MAs, and 20–23% DMAs. H51R, I136T, R173W, C61W, and W203C had the highest amount of starting material iAs (83–100%) and lowest DMAs (0–8%). These results demonstrate that the eight nonsynonymous missense variants of hAS3MT have lower arsenic methylation capacity compared with wild-type hAS3MT, from which we predict may lead to individual variations in arsenic methylation and slower clearance of arsenic from the body, factors that could increase the risk of arsenic-related diseases.

Kinetic Analysis of hAS3MT Polymorphic Enzymes. Kinetics governs fluxes of metabolites through intracellular pathways. Enzymes catalyze the individual steps of cellular reactions, and their rates dictate which pathways predominate. The rate of production of individual methylated species, and hence the PMI and SMI, depends on the kinetics of each step, which may vary in different polymorphic variants. How do the kinetic properties of the polymorphic enzymes compare with the wild type? The kinetic parameters for each substrate, As(III), MAs(III), and SAM, were individually determined for wild-type and variant hAS3MTs. With the TR-FRET assay, the first (As → MAs) (Figure 4A) and second (MAs → DMAs) (Figure 4B) methylation steps can be assayed independently.\textsuperscript{35} In both steps, wild-type hAS3MT exhibited the highest maximal rates (V\textsubscript{max}) compared with the polymorphic enzymes. The R251H and T306I variants showed higher V\textsubscript{max} values compared to the other polymorphic enzymes. The V\textsubscript{max} values of the I136T, R173W, M287T, and H51R variants were significantly lower than the others in both reaction steps.

The affinity (K\textsubscript{m}) of each enzyme for As(III) and MAs(III) was determined (Table 2). Wild-type and polymorphic hAS3MT enzymes each had K\textsubscript{m} values in the range of 1–2 μM, indicating that the amino acid substitutions did not affect binding of As(III) (except for C61S and W203C, which do not methylate As(III)). The apparent K\textsubscript{m} values for MAs(III) were lower than for As(III) for each enzyme, in the range of 0.4–0.8 μM, suggesting that MAs(III) is a better substrate than As(III). The exceptions were W203C, which does not methylate MAs(III), and C61S, which has a three-fold reduction in affinity for MAs(III).

The TR-FRET assay measures formation of SAH from SAM and thus cannot be used for determination of SAM kinetics,\textsuperscript{35} so the kinetics for SAM as substrate was determined by formation of DMAs from MAs(III) as a function of SAM concentration using HPLC–ICP–MS. This measures only the second methylation step but was used because the C61S variant cannot methylate As(III). The V\textsubscript{max} values for wild-type hAS3MT, R251H, and T306I were similar to each other and were higher than other polymorphic enzymes (Figure 4C). The affinity of each polymorphic enzyme for SAM was similar to that of the wild type, in the range of 14–30 μM with one exception. The K\textsubscript{m} for I136T for SAM was 137 μM, eight-fold lower affinity than wild-type hAS3MT. From the homology model of hAS3MT, Ile136 is in the SAM binding domain, suggesting that a threonine substitution affects folding of the SAM binding domain.

The specificity constant or catalytic efficiency (k\textsubscript{cat}/K\textsubscript{m}) of an enzyme is a useful metric for comparing the relative rates of an
enzyeme for multiple substrates. The $k_{cat}/K_m$ of the wild type and SNPs was calculated (Table 2). The wild type specificity constant for MAs(III) was three-fold higher than for As(III), clearly showing that the methylated species is a better substrate for hAS3MT than inorganic arsenic. In every case, the catalytic efficiency of the SNPs was lower than wild-type hAS3MT, unambiguously demonstrating that each single amino acid substitution resulted in a less active enzyme.

**Thermal Stability of the Eight Polymorphic hAS3MTs.**

A possible consequence of a single amino substitution in a protein is improper folding that results in decreased stability. The thermal stability of the seven active missense variants was compared with wild-type hAS3MT (Table 3). The enzymes were incubated at 42 °C for varying lengths of time followed by determination of methylation activity (Figure 5). Wild-type hAS3MT had a half-life of 20 min at 42 °C. The SNPs lost activity much faster, with half-lives ranging from 1–5 min. R251H has relatively higher stability compared to other polymorphic enzymes, which may in part account for its higher catalytic efficiency compared to the others (Table 2). However, these in vitro studies do not rule out the possibility of in vivo stabilizing or destabilizing factors.

**DISCUSSION**

A growing number of single nucleotide polymorphisms in the gene for human AS3MT have been identified. The goal of this study was to characterize the products of SNPs that produce single amino acid changes in the AS3MT enzyme. To date, only the three most frequent in human populations, R173W (rs35232887), M287T (rs11191439), and T306I (rs34556438), have been studied. M287T, the most frequent polymorphism, has been associated with a lower SMI, that is, higher urinary MAs and lower DMAs, in various populations. This SNP has been associated with higher negative outcomes. For example, in individuals with the M287T polymorphism, they are at an increased risk of diabetes, premalignant arsenic skin lesions, basal cell carcinoma, and perhaps bladder cancer. On the other hand, there are no epidemiological studies of the R173W or T306I SNPs in human populations. Most individuals carrying these haplotypes are heterozygous, so each expresses a wild-type AS3MT gene, which affects the phenotype. A few homozygous M287T individuals have been identified, and these have higher MAs and lower DMAs compared with wild-type hAS3MT.

There are only a few biochemical studies of these SNPs. In a ground-breaking study, Wood et al. identified three non-synonymous SNPs in hAS3MT with single amino changes R173W, M287T, and T306I and examined the enzymatic activity of the three variants. In that study, the human cDNA was altered by site directed mutagenesis to introduce these substitutions. There was no detectable methylation activity. The R173W variant had only 5% the amount of immunoreactive protein and post-translational modifications. Cytosol containing the T306I variant had twice as much M287T immunoreactive protein in the cytosol, which did not appear to result from less rapid degradation. The
the means up to 10 μM of either As(III) or MAs(III). The data are the means ± SE (n = 3). *Activity was measured with the TR-FRET assay at 37 °C. The data are the means ± SE (n = 3). &Activity was measured with the TR-FRET assay at 0, 1, 2, and 5 min in the presence of 10 μM SAM, 0.5 mM GSH, 1 μM Trx, 0.3 μM TR, 0.03 mM NADPH, and As(III) at concentrations up to 10 μM using the TR-FRET assay at 37 °C. The data are the means ± SE (n = 3). #Activity was measured with the TR-FRET assay at 0, 1, 2, and 5 min in the presence of 10 μM SAM, 0.5 mM GSH, 1 μM Trx, 0.3 μM TR, 0.03 mM NADPH, and MAs(III) at concentrations up to 10 μM at 37 °C. *Activity was measured at 0, 5, 10, and 20 min in the presence of 10 μM MAs(III), 2.5 mM GSH, 1.5 μM TR, 1.4 μM NADPH, and SAM at concentrations up to 600 μM by HPLC–ICP–MS at 37 °C. *Indicates statistically significant differences (p < 0.02) in Vmax or Kcat values between wild-type hAS3MT and variants-catalyzed methylation.

Table 3. Temperature-Dependent Half-Life (t1/2) of hAS3MT and Polymorphic Variants

| Polymorphisms | t1/2 (min) |
|---------------|------------|
| WT            | 20.0 ± 1.5 |
| H51R          | 2.3 ± 0.8  |
| C61W          | 1.0 ± 0.5  |
| I136T         | 1.5 ± 0.6  |
| R173W         | 1.9 ± 0.5  |
| W203C         | no activity|
| R251H         | 5.0 ± 1.0  |
| M287T         | 2.7 ± 0.6  |
| T306I         | 3.1 ± 0.5  |

Proteins were incubated at 42 °C for 0, 2, 6, 10, and 15 min. The control was kept on ice for 15 min. Methylation activity was assayed at 37 °C with the TR-FRET assay using 1 μM hAS3MT and variants (or 10 μM C61W), 10 μM SAM, 1 μM Trx, 0.3 μM TR, 30 μM NADPH, 0.5 mM GSH, and 10 μM of either As(III) or MAs(III). The data are the means ± SE (n = 3). *<0.001 when compared with wild-type hAS3MT. **<0.05 when compared with wild-type hAS3MT.

Figure 5. Temperature stability of wild-type hAS3MT and polymorphic variants. Wild-type hAS3MT and variants were heated at 42 °C for the indicated times, following which methylation activity was assayed with the TR-FRET assay at 37 °C using 1 μM enzyme, 10 μM SAM, 1 μM Trx, 0.3 μM TR, 30 μM NADPH, 0.5 mM GSH, and 10 μM As(III) (or 10 μM MAs(III)) for C61W). The data are the mean ± SE (n = 3).

M287T enzyme had 3.5-fold more activity than the wild type after correction for the amount of immunoreactive protein. The Kcat of this variant was approximately 11 μM for As(III), about half the affinity of the wild type and 5 μM for SAM, about twice the affinity of the wild type. These values are significantly different from each other, but not enough to explain any physiological differences.

There was another notable biochemical study of the M287T variant. In this study, wild-type hAS3MT cDNA and a site-directed M287T mutant were expressed in E. coli, purified, and assayed using an assay including Trx and TR with or without GSH. In the absence of GSH, the ratio of DMAs to MAs was low. In the presence of GSH, significantly more MAs(III) was produced from As(III). GSH is the major intracellular thiol, so the activity in the presence of GSH is more likely to reflect the physiological activity. This is a significant finding, which led us to include Trx, TR, and GSH in our assays. In the presence of GSH, the Kcat for both wild-type hAS3MT and M287T enzymes was approximately 1.6 μM for As(III) and 0.7–0.8 μM for MAs(III). The Vmax values for both were relatively the same for both enzymes as well, approximately 6 pmol/μg protein/min with As(III) and 14–16 pmol/μg protein/min with MAs(III). From that study, the authors concluded that there were insufficient differences between the wild-type and M287T enzymes to account for differences in the SMI, and the reason for the increased susceptibility in individuals with the SNP could not be attributed to differences in catalytic activity between the variant and wild-type hAS3MT.

As valuable as these contributions were, they were not conclusive. Wood et al. used crude cytosolic preparations. Enzyme kinetics are meaningful only when conducted with purified enzymes. The hAS3MT enzymes used by Ding et al. had little activity, and methylation of iAs required equimolar or excess enzyme over substrate over long time periods. These are not catalytic conditions. At most a few turnovers would occur during the reaction, not sustained catalysis. Our approach was to use highly active purified enzymes to analyze the catalytic properties of the three most frequent exonic SNPs, as well as five additional less common ones, and correlate their activity and stability with structural information. We used a synthetic hAS3MT gene as the starting material for expression and mutant construction. We showed previously that the product
of the synthetic gene can be used in catalytic amounts with the Trx/TR/GSH assay. A large excess of substrate over enzyme ensures that there are multiple rounds of methylation during the assay time, which, with the TR-FRET assay, is linear up to 5 min.\(^{35}\) In addition, the TR-FRET assay allows the two methylation reactions (\(i\text{As} \rightarrow \text{MAs} \rightarrow \text{DMAs}\)) to be determined independently, an accomplishment not possible in previous studies. With this assay, it is clear that six of the variants had similar affinity for As(III) and MAs(III) as wild-type hAS3MT. The W203C enzyme lacked measurable activity. The C61W variant was not active with As(III), and Cys61 has been shown to be required for methylation of As(III).\(^{33}\)

The kinetics of AS3MT sheds light on its role in metabolism, how its activity is controlled, and how a drug or an agonist might affect the metabolism of arsenic. Kinetic analyses have predictive physiological value. Kinetics governs the rates of metabolic pathways in vivo, which, in turn, allows our body to respond to arsenic exposure. The \(K_m\) for SAM of the active variants was also similar to that of the wild type except for I136T, consistent with the location of Ile136 near the SAM binding site. With each variant the \(V_{\text{max}}\) was reduced, and none of the variants approached the catalytic efficiency (\(k_{\text{cat}}/K_m\)) of the wild-type enzyme.

From the kinetics, we can conclude that each single amino acid substitution produces a less active enzyme. What is the connection between the substitution and the effect on activity? The homology structural model is informative.\(^{33}\) The structure of a protein is the key to its function, allowing visualization of substrate and allosteric binding sites. The consequences of amino acid substitutions in polymorphic variants are most easily understood by the structural changes they produce. For that reason, we constructed the homology model of hAS3MT and mapped the location of the eight polymorphisms on its surface (Figure 1). His51, Cys61, and Ile136 are in the SAM binding domain. Arg173, Trp203, and Arg251 are in the arsenic binding domain. Met287 and Thr306 are in the C-terminal domain. The PolyPhen2 score of each polymorphic enzyme was calculated. A high PolyPhen2 score indicates possible deleterious effects on the structure and activity of an enzyme. The M287T enzyme has a low PolyPhen2 score, which suggests little effect on hAS3MT structure. T306I has an intermediate score. H51R, C61W, R173W, I136T, and W203C have higher PolyPhen2 scores, predicting possibly harmful effects on the enzyme structure and reduced catalytic activity (Supplemental Table S10). Arg173 is in the As(III) binding site, so we predict that the R173W substitution may affect affinity for As(III).\(^{40}\) A C61W eliminates one of the four conserved cysteine residues (Cys32, Cys61, Cys156, and Cys206) involved in substrate binding and specificity. The C61W substitution prevents formation of a disulfide bond between Cys44 and Cys61 that is required for As(III) methylation. As predicted, the C61W enzyme methylated MAs(III) but was unable to methylate As(III). His51 is located near the start of the N-terminal domain but not near the SAM binding site, and the H51R substitution does not affect the \(K_m\) for SAM. In contrast, Ile is near the SAM binding site, and the I136T substitution reduces the affinity for SAM eight-fold.

All of the substituted residues are on the surface of the protein except for Thr306, which is buried inside the enzyme, so a T306I substitution is likely to disrupt the structure. The M287T SNP has been proposed to lower the SMI by specifically reducing the rate of the second methylation step.\(^{24}\) However, our results indicate that the first and second methylation steps are reduced by about the same amounts (78% and 75%, respectively), so there must be some other explanation. Met287 is located on the surface at the entrance to a cleft in AS3MT to which small molecule inhibitors bind (Figure 6).\(^{32}\) We proposed that this cleft is an allosteric site that binds physiological molecules that regulate methylation activity by modulating a conformational change at the cleft. We speculate that the M287T substitution hinders binding of putative modulators or retards the allosteric conformational change, reducing the rate of methylation of this variant. This property is consistent with observed epidemiological studies of individuals with the M287T polymorphism.

Another factor that contributes to the reduced activity of most the variants is that they are less stable than the wild type. From measurements of temperature stability, the variants denature between 4- and 20-fold faster than wild-type hAS3MT. Each of the eight identified SNPs is thus deleterious to one degree or another because it destabilizes the structure of the enzyme. The few examples of protective AS3MT polymorphisms are located outside of the coding sequence in putative regulatory elements.

In conclusion, using purified hAS3MT variants, we demonstrate that the eight identified amino acid substitutions in hAS3MT led to decreased catalytic activity through decreased affinity for As(III) or SAM and lower stability. The loss of methylation capacity could lead to increased harmful responses to environmental arsenic. Since arsenic levels in food and water in the United States and other developed countries are generally below the EPA and WHO recommended levels, there is little selective pressure against detrimental genotypes. In contrast, in regions of the world with high arsenic exposure,
increased expression of AS3MT is protective because it leads to faster clearance of arsenic from the body.

**REFERENCES**

(1) Mandal, B. K., and Suzuki, K. T. (2002) Arsenic round the world: a review. *Talanta* 58, 201–235.
(2) Naujokas, M. F., Anderson, B., Ahsan, H., Aposhian, H. V., Graziano, J. H., Thompson, C., and Suk, W. A. (2013) The broad scope of health effects from chronic arsenic exposure: update on a worldwide public health problem. *Environ. Health Perspect.* 121, 295–302.
(3) Thomas, D. J., and Rosen, B. P. (2013) Arsenic methyltransferases, in *Encyclopedia of Metalloproteins* (Kretsinger, R. H., Uversky, V. N., and Permyakov, E. A., Eds.) pp 138–143, Springer New York, New York.
(4) Zhu, Y. G., Yoshinaga, M., Zhao, F. J., and Rosen, B. P. (2014) Earth abides arsenic biotransformations. *Annu. Rev. Earth Planet. Sci.* 42, 443–467.
(5) Vahter, M. (2002) Mechanisms of arsenic biotransformation. *Toxicology* 181–182, 211–217.
(6) Dopp, E., Hartmann, L. M., Florea, A. M., von Recklinghausen, U., Pieper, R., Shokohb, B., Rettenmeier, A. W., Hirner, A. V., and Obe, G. (2004) Uptake of inorganic and organic derivatives of arsenic associated with induced cytotoxic and genotoxic effects in Chinese hamster ovary (CHO) cells. *Toxicol. Appl. Pharmacol.* 201, 156–165.
(7) Petrick, J. S., Ayala-Fierro, F., Cullen, W. R., Carter, D. E., and Vasken Aposhian, H. (2000) Monomethylarsenous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. *Toxicol. Appl. Pharmacol.* 163, 203–207.
(8) Styblo, M., Del Razo, L. M., Vega, L., Gernolec, D. R., LeCluyse, E. L., Hamilton, G. A., Reed, W., Wang, C., Cullen, W. R., and Thomas, D. J. (2000) Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. *Arch. Toxicol.* 74, 289–299.
(9) Styblo, M., Droboa, Z., Jaspers, I., Lin, S., and Thomas, D. J. (2002) The role of biomethylation in toxicity and carcinogenicity of arsenic: a research update. *Environ. Health Perspect.* 110, 767–771.
(10) Gong, Z., Lu, X., Cullen, W. R., and Chris Le, X. (2001) Unstable trivalent arsenic metabolites, monomethylarsonous acid and dimethylarsinous acid. *J. Anal. At. Spectrom.* 16, 1409–1413.
(11) Le, X. C., Lu, X., Ma, M., Cullen, W. R., Aposhian, H. V., and Zheng, B. (2000) Speciation of key arsenic metabolic intermediates in human urine. *Anal. Chem.* 72, 5172–5177.
(12) Antonelli, R., Shao, K., Thomas, D. J., Sams, R., and Cowden, J. (2014) AS3MT, GSTO, and PNP polymorphisms: impact on arsenic methylation and implications for disease susceptibility. *Environ. Res.* 132, 156–167.
(13) Engstrom, K. S., Vahter, M., Fletcher, T., Leonardi, G., Goessler, W., Gunzau, E., Koppova, K., Rudnai, P., Kumar, R., and Broberg, K. (2015) Genetic variation in arsenic (+3 oxidation state) methyl-transferase (AS3MT), arsenic metabolism and risk of basal cell carcinoma in a European population. *Environ. Mol. Mutagen.* 56, 60–69.
(14) Huang, Y. K., Tseng, C. H., Huang, Y. L., Yang, M. H., Chen, C. J., and Hsueh, Y. M. (2007) Arsenic methylation capability and hypertension risk in subjects living in arseniass-hyperendemic areas in southwestern Taiwan. *Toxicol. Appl. Pharmacol.* 218, 135–142.
(15) Schlawicke Engstrom, K., Broberg, K., Concha, G., Nermell, B., Warholm, M., and Vahter, M. (2007) Genetic polymorphisms influencing arsenic metabolism: evidence from Argentina. *Environ. Health Perspect.* 115, 599–605.
(16) Hansen, J. M. (2006) Oxidative stress as a mechanism of teratogenesis. *Birth Defects Res., Part C* 78, 293–307.
(17) Rosen, B. P., and Tamas, M. J. (2010) Arsenic transport in prokaryotes and eukaryotic microbes. *Adv. Exp. Med. Biol.* 679, 47–55.
(18) Huang, J. H., Scherr, F., and Matzner, E. (2007) Demethylation of dimethylarsinic acid and arsenobetaine in different organic soils. *Water, Air, Soil Pollut.* 182, 31–41.
(19) Shaftry, B. S. (2007) SNPs in disease gene mapping, medicinal drug development and evolution. *J. Hum. Genet.* 52, 871–880.
(20) Droboa, Z., Del Razo, L. M., Garcia-Vargas, G. G., Sanchez-Pena, L. C., Barrera-Hernandez, A., Styblo, M., and Loomis, D. (2013) Environmental exposure to arsenic, AS3MT polymorphism and prevalence of diabetes in Mexico. *J. Exposure Sci. Environ. Epidemiol.* 23, 151–155.
(21) Pierce, B. L., Tong, L., Argos, M., Gao, J., Farzana, J., Roy, S., Paul-Brutus, R., Rahaman, R., Rahikhu-Zaman, M., Parvez, F., Ahmed, A., Qasem, I., Hore, S. K., Alam, S., Islam, T., Harjes, J., Sarwar, G., Slavkovich, V., Gamble, M. V., Chen, Y., Yunus, M., Rahman, M., Baron, J. A., Graziano, J. H., and Ahsan, H. (2013) Arsenic metabolism efficiency has a causal role in arsenic toxicity: Mendelian randomization and gene-environment interaction. *Int. J. Epidemiol.* 42, 1862–1871.

**AUTHOR INFORMATION**

**Corresponding Author**

*E-mail: brosen@fiu.edu. Phone: (+1) 305-348-0657. Fax: (+1) 305-348-0651.*

**ORCID**

**Barry P. Rosen:** 0000-0002-5230-4271

**Funding**

This work was supported by National Institutes of Health Grant No. R01 ES023779.

**Notes**

The authors declare no competing financial interest.

**ACKNOWLEDGMENTS**

We thank Drs. Donald W. Bowden, Director, Center for Diabetes Research, Wake Forest School of Medicine, and Helen Tempest, Department of Human and Molecular Genetics, Florida International University Herbert Wertheim College of Medicine, for advice and suggestions on the genetics of arsenic metabolism.

**ABBREVIATIONS**

AS3MT, As(III) SAM methyltransferase; As(III), arsenite; DMAs(III), dimethylarsenite; DMAs(V), dimethylarsenate; ESP, Exome Sequencing Project; EXAC, Exome Aggregation Consortium; GSH, reduced glutathione; LB medium, Luria-Bertani medium; MAs(III), methylyarsenite; MAs(V), methylarsenate; MBP, malate-binding protein; MAF, minor allele frequency; PMI, primary methylation index; Rs, reference SNP ID; SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine; SNPs, single nucleotide polymorphisms; SMI, secondary methylation index; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; TR-FRET, time-resolved Förster resonance energy transfer; TCEP, tris(2-carboxyethyl)phosphine; TMA(III), trimethylarsine; Trx, thioredoxin; TR, thioredoxin reductase
Chemical Research in Toxicology

(22) Valenzuela, O. L., Droba, Z., Hernandez-Castellanos, E., Sanchez-Pena, L. C., Garcia-Vargas, G. G., Borja-Aburto, V. H., Styblo, M., and Del Razo, L. M. (2009) Association of AS3MT polymorphisms and the risk of premalignant arsenic skin lesions. Toxicol. Appl. Pharmacol. 239, 200–207.

(23) Beebe-Dimmer, J. L., Iyer, P. T., Nriagu, J. O., Keele, G. R., Melta, S., Meliker, J. R., Lange, E. M., Schwartz, A. G., Zuluhe, K. A., Schottenfeld, D., and Cooney, K. A. (2012) Genetic variation in glutathione S-transferase omega-1, arsenic methyltransferase and methylene-tetrahydrofolate reductase, arsenic exposure and bladder cancer: a case-control study. Environ. Health 11, 43.

(24) Agusa, T., Fujihara, J., Takeshita, H., and Iwata, H. (2011) Individual variations in inorganic arsenic metabolism associated with AS3MT genetic polymorphisms. Int. J. Mol. Sci. 12, 2351–2382.

(25) Engstrom, K., Vahter, M., Milak, S. C., Concha, G., Nermell, B., Raqi, R., Cardozo, A., and Broberg, K. (2010) Polymorphisms in arsenic(+III oxidation state) methyltransferase (AS3MT) predict gene expression of AS3MT as well as arsenic metabolism. Environ. Health Perspect. 119, 182–188.

(26) Hsieh, R. L., Sun, C. T., Shiue, H. S., Chen, W. J., Huang, S. R., Lin, Y. C., Lin, M. I., Mu, S. C., Chen, R. J., and Hsueh, Y. M. (2017) Real-time PCR of polymorphism of arsenic metabolism genes to arsenic methylatation capacity and developmental delay in preschool children in Taiwan. Toxicol. Appl. Pharmacol. 321, 37–47.

(27) Lindberg, A. L., Kumar, R., Goessler, W., Thirumaran, R., Gurzau, E., Koppova, K., Rudnai, P., Leonardi, G., Fletcher, T., and Vahter, M. (2007) Metabolism of low-dose inorganic arsenic in a central European population: influence of sex and genetic polymorphisms. Environ. Health Perspect. 115, 1081–1086.

(28) Schlebusch, C. M., Gattepaille, L. M., Engstrom, K., Vahter, M., Jakobsson, M., and Broberg, K. (2015) Human adaptation to arsenic-rich environments. Mol. Biol. Evol. 32, 1544–1555.

(29) Schlebusch, C. M., Lewis, C. M., Jr., Vahter, M., Engstrom, K., Tito, R. Y., Oregan-Tito, A. J., Huerta, D., Polo, S. I., Medina, A. C., Brutsaert, T. D., Concha, G., Jakobsson, M., and Broberg, K. (2013) Possible positive selection for an arsenic-protective haplotype in Central European population: influence of sex and genetic polymorphisms. Environ. Health Perspect. 121, 53–58.

(30) Apata, M., Arriaza, B., Llop, E., and Moraga, M. (2017) Human adaptation to arsenic in Andean populations of the Atacama Desert. Am. J. Phys. Anthropol. 163, 192.

(31) Wood, T. C., Salavagionne, O. E., Mukherjee, B., Wang, L., Klump, B. A., Thomaes, B. A., Eckloff, B. W., Schaadt, D. J., Wieben, E. D., and Weinsbichoun, R. M. (2006) Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies. J. Biol. Chem. 281, 7364–7373.

(32) Hernandez, A., Xamena, N., Sekaran, C., Tokunaga, H., Sampayo-Reyes, A., Quinteros, D., Creus, A., and Marcos, R. (2008) High arsenic metabolic efficiency in AS3MT287Thr allele carriers. Pharmacogenet. Genomics 18, 349–355.

(33) Dheeman, D. S., Packianathan, C., Pillai, J. K., and Rosen, B. P. (2014) Pathway of human AS3MT arsenic methylation. Chem. Res. Toxicol. 27, 1979–1989.

(34) Chen, J., Sun, S., Li, C. Z., Zhu, Y. G., and Rosen, B. P. (2014) Biosensor for organoarsenical herbicides and growth promoters. Environ. Sci. Technol. 48, 1141–1147.

(35) Dong, H., Xu, W., Pillai, J. K., Packianathan, C., and Rosen, B. P. (2015) High-throughput screening-compatable assays of As(III) S-adenosylmethionine methyltransferase activity. Anal. Biochem. 480, 67–73.

(36) Marapakala, K., Qin, J., and Rosen, B. P. (2012) Identification of catalytic residues in the As(III) S-adenosylmethionine methyltransferase. Biochemistry 51, 944–951.

(37) Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular cloning, a laboratory manual, Cold Spring Harbor Laboratory, New York.

(38) Gill, S. C., and von Hippel, P. H. (1989) Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 182, 319–326.

(39) Maki, T., Hirota, W., Ueda, K., Hasegawa, H., and Azizur Rahman, M. (2009) Seasonal dynamics of biodegradation activities for dimethylarsinic acid (DMA) in Lake Kahokugata. Chemosphere 77, 36–42.

(40) Ajees, A. A., Marapakala, K., Packianathan, C., Sankaran, B., and Rosen, B. P. (2012) Structure of an As(III) S-adenosylmethionine methyltransferase: insights into the mechanism of arsenic biotransformation. Biochemistry 51, 5476–5485.

(41) DeLano, W. L. (2001) The PyMOL user’s manual, DeLano Scientific, San Carlos, CA.

(42) Adzhubei, I., Jordan, D. M., and Sunyaev, S. R. (2013) Predicting functional effect of human missense mutations using PolyPhen-2. Curr. Protoc Hum Genet., 7.20.1.

(43) Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680–685.

(44) Chen, J., Li, J., Jiang, X., and Rosen, B. P. (2017) Conserved cysteine residues determine substrate specificity in a novel As(III) S-adenosylmethionine methyltransferase from Aspergillus fumigatus. Mol. Microbiol. 104, 250–259.

(45) Huang, Y. L., Hsueh, Y. M., Huang, Y. K., Yip, P. K., Yang, M. H., and Chen, C. J. (2009) Urinary arsenic methylation capability and carotid atherosclerosis risk in subjects living in arsenicosis-hyperendemic areas in southwestern Taiwan. Sci. Total Environ. 407, 2608–2614.

(46) Chen, G. Q., Zhou, L., Styblo, M., Walton, F., Jing, Y., Weinberg, R., Chen, Z., and Wasman, S. (2003) Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res. 63, 1853–1859.

(47) Fagin, C. O. (1995) Understanding and increasing protein stability. Biochim. Biophys. Acta, Protein Struct. Mol. Enzymol. 1252, 1–14.

(48) Horton, J. R., Sawada, K., Nishimori, M., Zhang, X., and Cheng, X. (2001) Two polymorphic forms of human histamine methyltransferase: structural, thermal, and kinetic comparisons. Structure 9, 837–849.

(49) Beitz, E., Wu, B., Holm, L. M., Schultz, J. E., and Zechten, T. (2006) Point mutations in the arginase/arginine region in aquaporin 1 allow passage of urea, glycerol, ammonia, and protons. Proc. Natl. Acad. Sci. U. S. A. 103, 269–274.

(50) Ding, L., Saunders, R. J., Droba, Z., Walton, F. S., Xun, P., Thomas, D. J., and Styblo, M. (2012) Methylation of arsenic by recombinant human wild-type arsenic (+3 oxidation state) methyltransferase and its methionine 287 threonine (M287T) polymorphism: Role of glutathione. Toxicol. Appl. Pharmacol. 264, 121–130.

(51) Dong, H., Madegowa, M., Neftzi, A., Houghten, R. A., Giulianiotti, M. A., and Rosen, B. P. (2015) Identification of small molecule inhibitors of human As(III) S-adenosylmethionine methyltransferase (AS3MT). Chem. Res. Toxicol. 28, 2419–2425.